Bank of Montreal Can Has $936,000 Position in Masimo Corporation $MASI

Bank of Montreal Can lowered its holdings in shares of Masimo Corporation (NASDAQ:MASI) by 9.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,563 shares of the medical equipment provider’s stock after selling 565 shares during the period. Bank of Montreal Can’s holdings in Masimo were worth $936,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. grew its position in shares of Masimo by 0.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,673,252 shares of the medical equipment provider’s stock worth $278,764,000 after buying an additional 10,876 shares during the period. Durable Capital Partners LP bought a new position in Masimo during the first quarter worth $187,528,000. Alyeska Investment Group L.P. grew its holdings in Masimo by 24.9% in the first quarter. Alyeska Investment Group L.P. now owns 722,534 shares of the medical equipment provider’s stock worth $120,374,000 after purchasing an additional 143,899 shares during the period. Dimensional Fund Advisors LP grew its holdings in Masimo by 8.6% in the first quarter. Dimensional Fund Advisors LP now owns 703,378 shares of the medical equipment provider’s stock worth $117,172,000 after purchasing an additional 55,658 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Masimo by 26.3% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 471,041 shares of the medical equipment provider’s stock valued at $79,239,000 after purchasing an additional 98,063 shares in the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MASI has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. Wells Fargo & Company cut their target price on Masimo from $190.00 to $187.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Zacks Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Wall Street Zen upgraded shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, Piper Sandler raised their price objective on shares of Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $194.00.

Masimo Stock Down 0.9%

MASI opened at $151.12 on Friday. Masimo Corporation has a fifty-two week low of $133.70 and a fifty-two week high of $194.88. The firm has a market capitalization of $8.12 billion, a P/E ratio of -17.74 and a beta of 1.28. The company’s 50-day moving average is $145.83 and its 200 day moving average is $153.40. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The firm had revenue of $617.00 million during the quarter. Research analysts expect that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.